This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Socinski, M. A. Articles by Morris, D. Search for Related Content PubMed PubMed Citation Articles by Socinski, M. A. Articles by Morris, D.

Treatment of Non-small Cell Lung Cancer, Stage IV^*

ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)

^* From the University of North Carolina (Drs. Socinski and Morris), Chapel Hill, NC; University of New Mexico Health Sciences Center (Dr. Crowell), Albuquerque, NM; Northwestern University (Dr. Hensing), Evanston, IL; the Fox Chase Cancer Center (Dr. Langer), Philadelphia, PA; the Mt. Sinai Medical Center (Dr. Lilenbaum), New York, NY; and the Vanderbilt Ingram Cancer Center (Dr. Sandler), Nashville, TN.

Correspondence to: Mark A. Socinski, MD, FCCP, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB# 7305, Chapel Hill, NC 27599; e-mail: socinski{at}med.unc.edu

Background: Stage IV non-small cell lung cancer (NSCLC) remains a treatable but incurable disease.

Methods: A MEDLINE search was performed to identify pertinent peer-reviewed articles that addressed the questions posed for this section. The writing committee developed and graded recommendations, which were subsequently approved by the American College of Chest Physicians.

Results: Platinum-based doublets remain the standard of care in patients with good performance status (PS); there is no evidence that the addition of a third cytotoxic agent improves survival. Likewise, with only one exception, the addition of a new targeted or biological agent to platinum-based doublets does not improve survival. The one exception is the addition of bevacizumab, an antiangiogenic agent, to carboplatin/paclitaxel in patients with stage IV disease and good PS. Patients for whom bevacizumab is recommended must also be selected on the basis of histology (nonsquamous), absence of brain metastases and hemoptysis, and no indication for therapeutic anticoagulation. In patients with stage IV NSCLC and PS of 2, chemotherapy is recommended, but the optimal approach has not been defined. Elderly patients, defined as 70 years old, also derive benefit from chemotherapy. Most elderly patients should receive single-agent chemotherapy, but elderly patients with good PS and without significant comorbidities seem to derive a similar benefit from platinum-based doublets compared with their younger counterparts without a prohibitive difference in treatment toxicities. Because stage IV NSCLC is incurable, quality-of-life issues are important, and tools exist to monitor a patient’s quality of life during therapy. Last, patients need to be informed of the implication of the diagnosis of stage IV NSCLC and be educated about treatment options that are available to them.

Conclusions: Advances have been made in stage IV NSCLC, and the appropriate use of chemotherapy continues to evolve on the basis of well-designed clinical trials that address critical issues in this population.

Key Words: chemotherapy • non-small cell lung cancer • quality of life • targeted therapy